Gujarat Inject Intrinsic Value
Gujarat Inject intrinsic value. Gujarat Inject (GUJINJEC) median intrinsic value is ₹6.67 from 8 valuation models (range ₹5–₹16), vs current price ₹9.09 — -26.6% downside (Trading Above Calculated Value), margin of safety -36.3%. Read GUJINJEC dividend yield for the complete payout history and dividend yield track record.
GUJINJEC Valuation Methods Summary — DCF, Graham Number & P/E
Gujarat Inject intrinsic value across 8 models vs current price ₹9.09 — upside/downside and value range per method. For current market price and key ratios, visit GUJINJEC stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹6.60 | ₹5.28 - ₹7.92 | -27.4% | EPS: ₹0.30, Sector P/E: 22x |
| Book Value Method | asset | ₹13.33 | ₹12.00 - ₹14.66 | +46.6% | Book Value/Share: ₹6.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹16.00 | ₹14.40 - ₹17.60 | +76.0% | Revenue/Share: ₹8.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6.67 | ₹6.00 - ₹7.34 | -26.6% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹4.80 | ₹4.32 - ₹5.28 | -47.2% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹4.84 | ₹4.36 - ₹5.32 | -46.8% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹6.67 | ₹6.00 - ₹7.34 | -26.6% | ROE: 10.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹6.71 | ₹6.04 - ₹7.38 | -26.2% | EPS: ₹0.30, BVPS: ₹6.67 |
GUJINJEC Intrinsic Value vs Market Price — All Valuation Models
Gujarat Inject fair value range ₹5–₹16 vs current market price ₹9.09 across 8 valuation models. Compare with GUJINJEC fair value estimate to assess whether the stock is under or overvalued.
GUJINJEC Intrinsic Value Analysis — Undervalued or Overvalued?
Gujarat Inject median intrinsic value ₹6.67, current price ₹9.09 — Trading Above Calculated Value by 26.6%, margin of safety -36.3%.
What is the intrinsic value of GUJINJEC?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Gujarat Inject (GUJINJEC) is ₹6.67 (median value). With the current market price of ₹9.09, this represents a -26.6% variance from our estimated fair value.
The valuation range spans from ₹4.80 to ₹16.00, indicating ₹4.80 - ₹16.00.
Is GUJINJEC undervalued or overvalued?
Based on our multi-method analysis, Gujarat Inject (GUJINJEC) appears to be trading above calculated value by approximately 26.6%.
GUJINJEC Financial Health — Key Ratios vs Industry Benchmarks
Gujarat Inject financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.20 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 10.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GUJINJEC Cash Flow Quality — Operating & Free Cash Flow
Gujarat Inject operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹-6 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2020 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |